<DOC>
	<DOCNO>NCT00784017</DOCNO>
	<brief_summary>This multicentric phase III study design assess efficacy safety recombinant asparaginase ( rASNase ) comparison Asparaginase medac™ treatment child de novo ALL</brief_summary>
	<brief_title>Comparative Efficacy Safety Two Asparaginase Preparations Children With Previously Untreated Acute Lymphoblastic Leukaemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Previously untreated Tlineage precursor Blineage ALL Patients must morphological proof ALL diagnosis must make bone marrow morphology 25 % blast Written inform consent Treatment accord DCOG ALL 10 protocol Mature Blineage ALL Patients secondary ALL Known allergy ASNase preparation General health status accord Karnofsky / Lansky score &lt; 40 % Preexisting know coagulopathy ( e.g . haemophilia ) Preexisting pancreatitis Liver insufficiency ( Bilirubin &gt; 50 µmol/L ; SGOT/SGPT &gt; 10 x ULN ) Other current malignancy Pregnancy ( plan existent ) , breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Children previously untreated acute lymphoblastic leukemia</keyword>
</DOC>